Drug-induced hypersomnia ; Лекарственно-индуцированная гиперсомния

Authors: T. M. Ostroumova, O. D. Ostroumova, A. V. Filippova, T. F. Guseva, Т. М. Остроумова, О. Д. Остроумова, А. В. Филиппова, Т. Ф. Гусева

Source: Neurology, Neuropsychiatry, Psychosomatics; Vol 13, No 2 (2021); 117-122 ; Неврология, нейропсихиатрия, психосоматика; Vol 13, No 2 (2021); 117-122 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2021-2

Subject Terms: побочные эффекты, drug-induced hypersomnia, medication, adverse drug reaction, side effects, лекарственно-индуцированная гиперсомния, лекарственные средства, нежелательные лекарственные реакции

File Description: application/pdf

Relation: https://nnp.ima-press.net/nnp/article/view/1550/1229; https://nnp.ima-press.net/nnp/article/view/1550/1237; Sateia MJ. International classification of sleep disorders – third edition: highlights and modifications. Chest. 2014 Nov;146(5):1387-94. doi:10.1378/chest.14-0970; Полуэктов МГ. Диагностика и лечение расстройств сна. Москва; 2016. С. 193-7.; Gupta R, Seithikurippu R, Almeneessier A, et al. Hypersomnolence and Traffic Safety. Sleep Med Clin. 2017 Sep;12(3):489-99. doi:10.1016/j.jsmc.2017.03.018. Epub 2017 Jun 8.; Pagel JF. Drug-Induced Hypersomnolence. Sleep Med Clin. 2017 Sep;12(3):383-93. doi:10.1016/j.jsmc.2017.03.011. Epub 2017 Jun 10.; Gastel AV. Drug-Induced Insomnia and Excessive Sleepiness. Sleep Med Clin. 2018 Jun;13(2):147-59. doi:10.1016/j.jsmc.2018.02.001. Epub 2018 Mar 28.; Pagel JF, Pandi-Perumal SR, editors. Primary Care Sleep Medicine: A Practical Guide. New York: Springer; 2014. doi:10.1007/978-1-4939-1185-1; Tisdale JE, Miller DA. Drug Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda, Md: American Society of Health-System Pharmacists; 2018. 1399 р.; Dauvilliers Y, Buguet A. Hypersomnia. Dialogues Clin Neurosci. 2005;7(4):347-56. doi:10.31887/DCNS.2005.7.4/ydauvilliers; Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000 Apr;59(4):865-89. doi:10.2165/00003495-200059040-00014; Drakatos P, Marples L, Muza R, et al. NREM parasomnias: a treatment approach based upon a retrospective case series of 512 patients. Sleep Med. 2019 Jan;53:181-8. doi:10.1016/j.sleep.2018.03.021. Epub 2018 Apr 10.; Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev. 2012 Dec 12;12:CD009138. doi:10.1002/14651858.CD009138.pub2; Katona CL, Hunter BN, Bray J. A doubleblind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry. 1998 Feb;13(2):100-8. doi:10.1002/(sici)1099-1166(199802)13:23.0.co;2-j; Fagiolini A, Albert U, Ferrando L, et al. A randomized, double-blind study comparing the efficacy and safety of trazodone once-a-day and venlafaxine extended-release for the treatment of patients with major depressive disorder. Int Clin Psychopharmacol. 2020 May;35(3):137-46. doi:10.1097/YIC.0000000000000304; Rizo C, Deshpande A, Ing A, et al. A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants. J Affect Disord. 2011 Apr;130(1-2):290-3. doi:10.1016/j.jad.2010.07.027. Epub 2010 Aug 12.; Schweitzer PK, Griffin KS. Hypersomnia due to Medication or Substance. In: Reference Module in Neuroscience and Biobehavioral Psychology. Elsevier; 2017. doi:10.1016/b978-0-12-809324-5.01065-8; Crocco EA, Cruz-Ortiz С, Camfield K. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych. 2017 Mar;4(1):33-46. doi:10.1007/s40501-017-0102-4. Epub 2017 Feb 10.; Miller DD, Pharm D. Atypical Antipsychotics: Sleep, Sedation, and Efficacy. Prim Care Companion. J Clin Psychiatry. 2004;6(Suppl 2):3-7.; Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. N Engl J Med. 2005 Sep 22;353(12):1209-23. doi:10.1056/NEJMoa051688. Epub 2005 Sep 19.; Elger CE, Stefan H, Mann A, at al. A 24-week multicenter, randomized, doubleblind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res. 2010 Feb;88(2-3):255-63. doi:10.1016/j.eplepsyres.2009.12.003. Epub 2010 Jan 12.; Bonanni E, Galli R, Maestri M, et al. Daytime Sleepiness in Epilepsy Patients Receiving Topiramate Monotherapy. Epilepsia. 2004 Apr;45(4):333-7. doi:10.1111/j.0013-9580.2004.47803.x; Reife R, Pledger G, Wu S. Topiramate as Add-On Therapy: Pooled Analysis of Randomized Controlled Trials in Adults. Epilepsia. 2000;41(S1):66-71. doi:10.1111/j.1528-1157.2000.tb02175.x; Biton V, Krauss G, Vasquez-Santana B, et al. A randomized, doubleblind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures. Epilepsia. 2011 Feb;52(2):234-42. doi:10.1111/j.1528-1167.2010.02729.x. Epub 2010 Sep 30.; Нодель МР. Гиперсомния и циркадные нарушения при болезни Паркинсона. Неврология, нейропсихиатрия, психосоматика. 2016;8(4):45-50. doi:10.14412/2074-2711-2016-4-45-50; Левин ОС, Ляшенко ЕА. Нарушения сна при болезни Паркинсона. Фарматека. 2014;10(3):12-9.; Schweitzer PK, Randazzo AC. Drugs that disturb sleep and wakefulness. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th ed. Philadelphia: Elsevier; 2017. P. 480-98.; Rosen G, Harris AK, Liu M, et al. The effects of Dexamethasone on sleep in young children with Acute Lymphoblastic Leukemia. Sleep Med. 2015 Apr;16(4):503-9. doi:10.1016/j.sleep.2014.11.002. Epub 2015 Feb 2.; Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5. doi:10.1093/sleep/14.6.540; Gros P, Videnovic A. Overview of Sleep and Circadian Rhythm Disorders in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):119-30. doi:10.1016/j.cger.2019.09.005. Epub 2019 Sep 6.; Сычев ДА, Остроумова ОД, Переверзев АП и др. Лекарственные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фарматека. 2020; (6):113-26. doi:10.18565/pharmateca.2020.6.113-126; Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Greenblatt Clin Pharmacol. 1981 Aug;30(2):239-45. doi:10.1038/clpt.1981.154

Availability: https://nnp.ima-press.net/nnp/article/view/1550
https://doi.org/10.14412/2074-2711-2021-2-117-122